CoChat

Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future

Open access
Lampe, Harriet, Tam, Laura, Hansen, Aaron R. · 2024 · Frontiers in Pharmacology

The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.

Abstract

Metastatic castrate resistant prostate cancer (mCRPC) continues to have poor survival rates due to limited treatment options. Bi-specific T cell engagers (BiTEs) are a promising class of novel immunotherapies with demonstrated success in haematological malignancies and melanoma. BiTEs developed for tumour associated antigens in prostate cancer have entered clinical testing. These trials have been hampered by high rates of treatment related adverse events, minimal or transient anti-tumour efficacy and generation of high titres of anti-drug antibodies. This paper aims to analyse the challenges faced by the different BiTE therapy constructs and the mCRPC tumour microenvironment that result in therapeutic resistance and identify possible strategies to overcome these issues.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2024.1399802

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 100 references

Research works printed but not linked: 6

  1. 2010, Immunogenicity testing of therapeutic protein products - developing and validating assays for anti-drug antibody detection - guidelines for Industry
  2. Agency, 2017, Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins
  3. 2017, Aptevo therapeutics and MorphoSys end joint development and - commercialization agreement for mor209/es414
  4. 2022, Harpoon therapeutics reports fourth quarter and full year 2021 financial results and provides corporate update<harpoon-therapeutics-reports-fourth-quarter-and.pdf>
  5. 2019, Study with bispecific antibody engaging T-cells
  6. 2023, An interactive website for SEER cancer statistics: surveillance Research Program

Cited by

Metadata

Authors
Lampe, H., Tam, L., & Hansen, A. R.
Affiliations
Queensland Health (AU)
Corresponding author
Hansen, Aaron R.
Venue
Frontiers in Pharmacology
Published
2024-05-30
Volume
15
Pages
1399802-1399802
ISSN
1663-9812 (ISSN-L)
OpenAlex
W4399178517
Cited by
21
References
100
Citations by year
2026: 6 · 2025: 15
FWCI
1.55
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
bispecific T-cell engagers, metastatic castration-resistant prostate cancer, immunotherapy, tumor microenvironment, anti-drug antibodies, treatment-related adverse events, treatment resistance, tumor-associated antigens

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.